Trials / Completed
CompletedNCT01397578
A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter, Phase II Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 91 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of MABT5102A on brain amyloid burden (as assessed by amyloid PET imaging) and other biomarkers in patients with mild to moderate Alzheimer's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MABT5102A | Repeating subcutaneous injection |
| DRUG | MABT5102A | Repeating intravenous infusion |
| DRUG | placebo | Repeating subcutaneous injection |
| DRUG | placebo | Repeating intravenous infusion |
Timeline
- Start date
- 2011-08-31
- Primary completion
- 2014-04-30
- Completion
- 2014-04-30
- First posted
- 2011-07-19
- Last updated
- 2017-07-12
Locations
29 sites across 3 countries: United States, France, Spain
Source: ClinicalTrials.gov record NCT01397578. Inclusion in this directory is not an endorsement.